PA-EXONE-CO.
9.11.2021 14:32:09 CET | Business Wire | Press release
The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, today announced that global manufacturing innovation leader Siemens is the first of several customers to place an advance purchase for the InnoventPro 3L metal 3D printer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109005404/en/
The InnoventPro is the world’s most advanced entry-level model for metal binder jetting — designed to take the easy-to-use features of the popular Innovent+ with patented Triple ACT advanced compaction technology and offer them with a bigger build area and the best speed and cutting-edge technology features of ExOne’s production-ready printers, such as the X1 25Pro® and X1 160Pro™.
The InnoventPro is slated to be on display for the first time in ExOne’s booth in Hall 12.0, Booth D69 at Formnext 2021 from Nov. 16-19 in Frankfurt, Germany. The machine is available for early-access machine customers in the first half of 2022, with broad availability to follow.
The InnoventPro features Siemens controls, which integrate with the printer drives, motors, sensors, as well as Siemens MindSphere IoT operating system, which powers ExOne’s Scout machine monitoring and analysis app.
Siemens will use the InnoventPro at its Charlotte Advanced Technology Collaboration Hub (CATCH) located in Charlotte, North Carolina to develop materials and processes before taking them to scale on the X1 160Pro.
“We’re very excited to feature the InnoventPro in our Technology Collaboration Hub, and we look forward to demonstrating how to integrate advanced additive manufacturing systems such as the InnoventPro into our end-to-end Digital Thread,” said Tim Bell, Head of Additive Manufacturing, Siemens Industry, Inc. The CATCH facility will leverage Siemens advanced hardware automation and software tools to continue the industrialization of additive manufacturing.
“ExOne is proud to continue offering Siemens technologies in our production-ready metal binder jetting systems, and we’re delighted that Siemens has purchased our new InnoventPro for its own manufacturing use,” said John Hartner, ExOne’s CEO. “Siemens technology continues to deliver important integration value to our production customers, and we’re confident our printer will deliver important manufacturing value to their operations as well.”
InnoventPro Feature Highlights
The affordable new InnoventPro is an all-new package built from the ground up that gives binder jetting customers the most advanced entry-level system on the market in a 3-liter build area of 125 x 220 x 100 mm. Features include:
- Triple ACT advanced compaction technology for precision dispensing, spreading, and compacting of ultra-fine MIM powders, delivering the industry-leading density, accuracy and repeatability that was proven on the Innovent+
- Now packaged with the same faster, smarter, recirculating printhead modules that come standard on ExOne production printers, enabling easy scalability to larger models
- The new printhead will be capable of speeds topping 700 cc/hour on the InnoventPro and printing a new class of patented NanoFuse™ binders embedded with nanoparticles to improve part quality and simplify sintering
- An innovative new comprehensive powder containment system, featuring the ergonomic X1 Powder Grip™ loading system, delivers ease-of-use and improved cleanliness
- Siemens MindSphere powers ExOne’s Scout machine monitoring and analysis app, part of ExOne’s strategy to surround its printers with a complete digital workflow. Scout is available today in the Apple App Store and on Google Play for use with ExOne production sand and metal 3D printers
The InnoventPro was designed by ExOne’s experienced binder jet engineering team based in Pittsburgh, Pennsylvania, and Gersthofen, Germany, with final manufacturing and assembly done in the United States.
Learn more about the InnoventPro at exone.com/innoventpro .
About ExOne
ExOne (Nasdaq: XONE) is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.
About Siemens Digital Industries
Siemens Digital Industries (DI) is an innovation leader in automation and digitalization. Closely collaborating with partners and customers, DI drives the digital transformation in the process and discrete industries. With its Digital Enterprise portfolio, DI provides companies of all sizes with an end-to-end set of products, solutions and services to integrate and digitalize the entire value chain. Optimized for the specific needs of each industry, DI’s unique portfolio supports customers to achieve greater productivity and flexibility. DI is constantly adding innovations to its portfolio to integrate cutting-edge future technologies. Siemens Digital Industries has its global headquarters in Nuremberg, Germany, and has around 75,000 employees internationally.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005404/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom